Skip Navigation


NDT Advance Access originally published online on June 25, 2007
Nephrology Dialysis Transplantation 2007 22(11):3221-3227; doi:10.1093/ndt/gfm361
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/11/3221    most recent
gfm361v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Trzonkowski, P.
Right arrow Articles by Rutkowski, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Trzonkowski, P.
Right arrow Articles by Rutkowski, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org


Treatment with recombinant human erythropoietin is associated with rejuvenation of CD8+ T cell compartment in chronic renal failure patients

Piotr Trzonkowski1, Alicja Debska-Slizien2, Andrzej Mysliwski1 and Boleslaw Rutkowski2

1Department of Histology and Immunology and 2Department of Nephrology, Transplantology and Internal Diseases, Medical University of Gdansk, Poland

Correspondence and offprint requests to: Piotr Trzonkowski, MD, PhD, Department of Histology and Immunology, Medical University of Gdansk, Ul. Debinki 1, 80-211 Gdansk, Poland. Email: ptrzon{at}amg.gda.pl; piotr.trzonkowski{at}surgery.oxford.ac.uk



  Abstract

Background. A growing body of evidence suggests an impact of rHuEpo on the immune system.

Methods. We assessed the impact of recombinant human erythropoietin (rHuEpo) on the immunity of 11 chronic renal failure patients who did not require haemodialysis. Naïve (Tn), central (Tcm) and effectory memory (Tcm, Tem, TemRA) subsets of CD8+ T cells, memory-CMV-specific CD8+ T cells, titres of anti-CMV antibodies and activity of NK cells were evaluated during the first year of rHuEpo administration.

Results. While the number of CD8 T cells did not change, significant change was found in their proportions. Percentage of Tn cells increased at the expense of Tcm cells. Appearing Tn cells were CD28+ increasing the total pool of CD28+ T cells. Together with decreasing number, Tcm cells changed to mainly CD28– Tcm cells. A ‘move’ towards the naïve compartment was also confirmed as the level of memory-CMV-specific CD8+ T cells decreased. Humoral immunity analysed as titres of anti-CMV antibodies as well as innate immunity measured as cytotoxicity of NK cells did not change during the follow-up.

Conclusions. We found that the administration of rHuEpo caused rejuvenation of cellular CD8+ T-dependent immunity in our patients.

Keywords: CD8+ T cells; CD28- T cells; central memory T cells; chronic renal failure; naïve T cells; recombinant human erythropoietin

Received for publication: 25. 1.07
Accepted in revised form: 11. 5.07


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.